{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:49:21Z","timestamp":1789332561464,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aim to determine the optimal dosing of midazolam continuous intravenous infusions for the treatment of pediatric refractory status epilepticus (RSE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>We searched Medline ALL, Embase, Embase Classic, Cochrane CENTRAL, and Web of Science in March 2023 and again in February 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection<\/jats:title>\n                    <jats:p>Randomized and non-randomized studies involving pediatric patients who received continuous midazolam for the treatment of RSE were eligible. Two authors independently conducted screening, full-text review, and data extraction. All methods followed PRISMA reporting guidelines. A narrative data synthesis was performed due to data heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Nineteen studies (448 patients) proved eligible; 3 were randomized control trials, while 16 were non-randomized studies. All studies had concerns regarding the risk of bias. Overall, midazolam aborted seizures in 363\/448 (81%) participants, with mean effective doses of 1.7\u201313.0\u2005\u03bcg\/kg\/min (0.17\u20130.78\u2005mg\/kg\/h). The remaining 85 participants (19%) who did not achieve seizure cessation received maximum doses of 1.7\u201332.0\u2005\u03bcg\/kg\/min (0.17\u20131.92\u2005mg\/kg\/h) prior to transitioning to another agent. Only 4 studies specified that boluses were given with each titration. Twelve studies reported that seizure cessation occurred at a mean time of 1.4\u2013546.0\u2005min (range 0\u2013720\u2005min) after midazolam initiation. In 8 of these studies, effective midazolam doses clustered at 2.0\u20135.0\u2005\u03bcg\/kg\/min (0.12\u20130.30\u2005mg\/kg\/h), with seizure cessation occurring within 10\u201370\u2005min in 204\/221 (92%) participants. Treatment-associated adverse events included intubation in 42\/221 (19%) and hypotension requiring fluids or no intervention in 18\/221 (8%). The studies did not differentiate between intubations performed as part of the study protocol or prior to midazolam infusion initiation nor did they specify whether hypotension was related to the co-administration of phenytoin or phenobarbital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Data supporting midazolam continuous infusion dosing are limited and heterogeneous. Our findings suggest a potential therapeutic window at rates of 2.0\u20135.0\u2005\u03bcg\/kg\/min (0.12\u20130.30\u2005mg\/kg\/h), with limited adverse risks. Earlier seizure cessation may be achieved by targeting this therapeutic window by starting treatment with higher doses than the typically used 1.0\u2005\u03bcg\/kg\/min (0.06\u2005mg\/kg\/h) or by rapidly escalating the dose.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Systematic Review Registration:<\/jats:bold>\n                      PROSPERO, identifier CRD42023413038.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1507325","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T01:18:47Z","timestamp":1744593527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Midazolam infusions for therapeutic management of pediatric refractory status epilepticus: a systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"K. Taneille","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"AlZadjali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawoud","family":"Al Nasseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Shoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecil D.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Basmaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole K.","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.seizure.2013.10.004","article-title":"Gaps and opportunities in refractory status epilepticus research in children: a multi-center approach by the pediatric status epilepticus research group (pSERG)","volume":"23","author":"Fern\u00e1ndez","year":"2014","journal-title":"Seizure"},{"key":"B2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.seizure.2018.05.012","article-title":"Pediatric refractory and super-refractory status epilepticus","volume":"68","author":"Vasquez","year":"2019","journal-title":"Seizure"},{"key":"B3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/archneur.1973.00490190019001","article-title":"Physiology of status epilepticus in primates","volume":"28","author":"Meldrum","year":"1973","journal-title":"Arch Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1111\/j.1528-1157.1993.tb05905.x","article-title":"Pathophysiological mechanisms of brain damage from status epilepticus","volume":"34","author":"Wasterlain","year":"1993","journal-title":"Epilepsia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1523\/jneurosci.0900-05.2005","article-title":"Status epilepticus increases the intracellular accumulation of GABAA receptors","volume":"25","author":"Goodkin","year":"2005","journal-title":"J Neurosci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1212\/01.wnl.0000180959.31355.92","article-title":"Treatment delay and the risk of prolonged status epilepticus","volume":"65","author":"Eriksson","year":"2005","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pediatrneurol.2007.02.012","article-title":"Efficacy of intravenous midazolam for status epilepticus in childhood","volume":"36","author":"Hayashi","year":"2007","journal-title":"Pediatr Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.1523\/jneurosci.4944-04.2005","article-title":"Trafficking of GABA A receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus","volume":"25","author":"Naylor","year":"2005","journal-title":"J Neurosci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/j.1875-9114.1985.tb03411.x","article-title":"Midazolam: the first water-soluble benzodiazepine; pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia","volume":"5","author":"Kanto","year":"1985","journal-title":"Pharmacotherapy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/wnl.44.10.1837","article-title":"Treatment of refractory generalized status epilepticus with continuous infusion of midazolam","volume":"44","author":"Parent","year":"1994","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/s0887-8994(98)00155-6","article-title":"Midazolam and pentobarbital for refractory status epilepticus","volume":"20","author":"Holmes","year":"1999","journal-title":"Pediatr Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/00003246-199307000-00011","article-title":"Midazolam in the treatment of status epilepticus in children","volume":"21","author":"Rivera","year":"1993","journal-title":"Crit Care Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1535759720928269","article-title":"Treatment of refractory convulsive status epilepticus: a comprehensive review by the American Epilepsy Society Treatments Committee","volume":"20","author":"Vossler","year":"2020","journal-title":"Epilepsy Curr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1212\/wnl.0000000000001673","article-title":"Time from convulsive status epilepticus onset to anticonvulsant administration in children","volume":"84","author":"Fern\u00e1ndez","year":"2304","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/s0920-1211(02)00085-2","article-title":"Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus","volume":"50","author":"Jones","year":"2002","journal-title":"Epilepsy Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.spen.2014.12.006","article-title":"Status epilepticus and refractory status epilepticus management","volume":"21","author":"Abend","year":"2014","journal-title":"Semin Pediatr Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B19","article-title":"Covidence","year":""},{"key":"B20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Br Med J"},{"key":"B22","volume-title":"R Studio: Integrated Development for R","year":"2020"},{"key":"B23","article-title":"R: A Language and Environment for Statistical Computing (2023)","year":""},{"key":"B24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.arcped.2021.09.011","article-title":"Comparison of the effect of continuous intravenous infusion of sodium valproate and midazolam on management of status epilepticus in children","volume":"28","author":"Abbaskhanian","year":"2021","journal-title":"Arch Pediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1177\/08830738050200060201","article-title":"Status epilepticus: clinical analysis of a treatment protocol based on midazolam and phenytoin","volume":"20","author":"Brevoord","year":"2005","journal-title":"J Child Neurol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/pcc.0000000000003043","article-title":"High-dose midazolam for pediatric refractory status epilepticus: a single-center retrospective study","volume":"23","author":"Daniels","year":"2022","journal-title":"Pediatr Crit Care Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1055\/s-0035-1557406","article-title":"Comparison of intravenous lidocaine and midazolam infusion for refractory convulsive status epilepticus in children","volume":"5","author":"Fallah","year":"2007","journal-title":"J Pediatric Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1097\/00003246-199909000-00043","article-title":"Midazolam coma for refractory status epilepticus in children","volume":"27","author":"Igartua","year":"1999","journal-title":"Crit Care Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1136\/adc.76.5.445","article-title":"Continuous midazolam infusion as treatment of status epilepticus","volume":"76","author":"Koul","year":"1997","journal-title":"Arch Dis Child"},{"key":"B30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1177\/08830738020170123002","article-title":"Eight-year study of childhood status epilepticus: midazolam infusion in management and outcome","volume":"17","author":"Koul","year":"2002","journal-title":"J Child Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/00003246-199204000-00009","article-title":"Intravenous midazolam for the treatment of refractory status epilepticus","volume":"20","author":"Kumar","year":"1992","journal-title":"Crit Care Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/0929-693x(96)81261-9","article-title":"Utilisation du midazolam intraveineux dans l\u2019\u00e9tat de mal convulsif de l'enfant","volume":"2","author":"Lemerle","year":"1995","journal-title":"Arch Pediatr"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1007\/s00134-006-0362-8","article-title":"High-dose midazolam therapy for refractory status epilepticus in children","volume":"32","author":"Morrison","year":"2006","journal-title":"Intensive Care Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.22037\/ijcn.v3i1.989","article-title":"Midazolam efficacy and side effects in generalized and partial refractory status epilepticus in children","volume":"3","author":"Omran","year":"2009","journal-title":"Iran J Child Neurol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.seizure.2004.12.005","article-title":"Efficacy of continuous midazolam infusion and mortality in childhood refractory generalized convulsive status epilepticus","volume":"14","author":"Ozdemir","year":"2005","journal-title":"Seizure"},{"key":"B36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.4103\/0972-5229.156476","article-title":"Complications during the management of pediatric refractory status epilepticus with benzodiazepine and pentobarbital infusions","volume":"19","author":"Patten","year":"2015","journal-title":"Indian J Crit Care Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/088307380201700203","article-title":"Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus","volume":"17","author":"Singhi","year":"2002","journal-title":"J Child Neurol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1097\/pcc.0000000000000900","article-title":"Refractory status epilepticus in children","volume":"17","author":"Tasker","year":"2016","journal-title":"Pediatr Crit Care Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.seizure.2019.06.011","article-title":"The effect of early midazolam infusion on the duration of pediatric status epilepticus patients","volume":"71","author":"Ulusoy","year":"2019","journal-title":"Seizure"},{"key":"B40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s100720200058","article-title":"Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus","volume":"23","author":"Ulvi","year":"2002","journal-title":"Neurol Sci"},{"key":"B41","first-page":"486","volume-title":"Continuous Infusion of Anti-Seizure Medications for Pediatric Refractory Status Epilepticus","author":"Vasquez","year":"2019"},{"key":"B42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0387-7604(00)00116-9","article-title":"Midazolam as a first-line agent for status epilepticus in children","volume":"22","author":"Yoshikawa","year":"2000","journal-title":"Brain Dev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"B44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40263-019-00690-8","article-title":"Pharmacotherapy for pediatric convulsive status epilepticus","volume":"34","author":"Singh","year":"2020","journal-title":"CNS Drugs"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2014report of the ILAE task force on classification of status epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/s0149-2918(97)80126-9","article-title":"Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units","volume":"19","author":"Fragen","year":"1997","journal-title":"Clin Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/pcc.0000000000003106","article-title":"Pharmacokinetic modeling of optimized midazolam and pentobarbital dosing used in treatment protocols of refractory status epilepticus","volume":"24","author":"Luchette","year":"2023","journal-title":"Pediatr Crit Care Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4103\/ijccm.ijccm_327_17","article-title":"A comparative study of midazolam and target-controlled propofol infusion in the treatment of refractory status epilepticus","volume":"22","author":"Masapu","year":"2018","journal-title":"Indian J Crit Care Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/wnp.0000000000000606","article-title":"The unease when using anesthetics for treatment-refractory status epilepticus: still far too many questions","volume":"37","author":"Opi\u0107","year":"2020","journal-title":"J Clin Neurophysiol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1507325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T01:18:49Z","timestamp":1744593529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1507325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":49,"alternative-id":["10.3389\/fped.2025.1507325"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1507325","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"article-number":"1507325"}}